TimePie 2026 Longevity Research Grant Program Now Open
We are excited to announce that the 2nd TimePie Longevity Research Grant Program is now open for applications from researchers around the world.
Fully funded by the profits of the TimePie Longevity Forum, this program is designed to support early-stage projects and promising scientists who have limited access to traditional funding.
Research Areas
Applicants should apply under one direction only:
Aging Biomarkers & Clocks Multi-omics–based aging assessment tools, with priority for clinically relevant models and those applicable to Chinese populations.
Immunosenescence & Inflammation Mechanisms of immune aging and chronic inflammation, including evaluation methods and potential intervention targets.
Intervention & Translational Research Anti-aging strategies (e.g., metabolic pathways, senolytics, nutrition), with priority for projects with preliminary data, clear translational potential, and measurable outcomes within 24 months.
Funding
3–4 projects worldwide
RMB 100,000–150,000 per project
Eligibility
PhD holders under 40
Based in universities, research institutes, or medical institutions (or other non-profit research/clinical settings)
Ability to conduct independent research
Innovative ideas or preliminary data, but limited access to major funding
Timeline
Application deadline: May 31, 2026
Results announcement: September 2026
Application
Please send the following materials before the deadline to: 📩 science.funding@timepie.com
Project proposal (template available via QR code; includes research plan, methods, and expected outcomes)
CV (including education, professional experience, and research achievements)
Proof of institutional affiliation (e.g., employment letter or contract)
Project Terms & Reporting
Selected projects will sign a funding agreement with TimePie. Grants will be disbursed in a one-time payment. Awardees are required to submit a progress report within 24 months of signing. Adjustments to the reporting timeline may be discussed if necessary.




